SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Correction Corporation of America of Class Action Lawsuit and Upcoming Deadline – CXW

NEW YORK, Oct. 09, 2016 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Correction Corporation of America (“CCA” or the “Company”) (NYSE: CXW ) and certain of its officers.   The class action, filed in United States District Court, Middle District of Tennessee, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired CCA securities between February 27, 2012 and August 17, 2016 both dates inclusive (the “Class Period”).  This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”). 

If you are a shareholder who purchased CCA securities during the Class Period, you have until October 24, 2016 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. 

[Click here to join this class action]

CCA, together with its subsidiaries, owns and operates privatized correctional and detention facilities in the United States. The Company owns, operates, and manages prisons and other correctional facilities, and provides inmate residential and prisoner transportation services for governmental agencies.  As of 2015, CCA was the largest private corrections company in the United States, and manages more than 65 correction and detention facilities in 19 states and the District of Columbia.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) CCA’s facilities lacked adequate safety and security standards and were less efficient at offering correctional services than the Federal Bureau of Prisons’ (“BOP”) facilities; (ii) CCA’s rehabilitative services for inmates were less effective than those provided by BOP; (iii) consequently, the U.S. Department of Justice (“DOJ”) was unlikely to renew and/or extend its contracts with CCA; and (iv) as a result of the foregoing, CCA’s public statements were materially false and misleading at all relevant times. 

On August 18, 2016, Deputy Attorney General Sally Yates announced the DOJ’s decision to end its use of private prisons, including those operated by CCA, after officials concluded that the facilities are both less safe and less effective at providing correctional services than those run by the federal government. 

On this news, CCA’s share price fell $9.65, or 39.45%, to close at $17.57 on August 18, 2016.  

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

 

CONTACT: Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 32

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 41

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 37

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 36

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Growth of Middle-Class Investors through Mutual Fund Ownership

Updated Category News Views 149

Mutual Funds and the Rise of the Middle-Class Investor Over recent years, mutual fund ownership has surged among middle-class families. According to insights from the Investment Company Institute (ICI), this trend signifies a vital transition as middle-income households increasingly seek investment opportunities. The growing presence of mutual funds in the American...

Continue Reading
Rques Exchange Reinforces Its Brand with Compliance Strategy

Updated Category News Views 180

Rques Exchange Reinforces Brand with Regulatory Frameworks Rques Exchange is taking significant steps to enhance its brand by emphasizing its commitment to regulatory alignment, operational transparency, and governance integrity in various markets. With global authorities increasingly scrutinizing digital asset platforms, Rques aims to position itself as a technology...

Continue Reading
Business Growth and Confidence: Provident Bank's Insights

Updated Category News Views 120

Increasing Business Confidence for the Future Recently, Provident Bank, a prominent financial institution based in New Jersey, conducted an enlightening Economic Outlook survey. This survey reflects the sentiments of 1,000 business leaders regarding the 2025 economic prospects. The results showcase a robust sense of optimism and confidence among businesses as they look...

Continue Reading
Performance Food Group Co: A Five-Year Stock Journey

Updated Category News Views 219

Unlocking the Value of Investment in Performance Food Group Co Performance Food Group Co (NYSE: PFGC) has delivered impressive returns over the last five years, standing out in the competitive market landscape. With an annualized return that has surpassed the market by 9.42%, investors have seen an average growth rate of around 24.5%. This stock is not just another entry...

Continue Reading
Understanding Rathbones Group Plc's Disclosure Requirements

Updated Category News Views 227

Key Information on Disclosure Requirements Understanding how companies disclose their shareholding is crucial for investors and stakeholders alike. Rathbones Group Plc plays an essential role in managing these disclosures, particularly regarding relevant securities that represent substantial interests in listed companies. Full Name of the Discloser The full name of the...

Continue Reading